PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE TO STD THER FOL

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是比较环磷酰胺/氟达拉滨方案与标准CVP对照组治疗的低级别淋巴瘤患者的缓解率、进展时间和生存率。该研究还将确定抗cd20维持对进展和生存时间的影响，以及随着时间的推移对淋巴细胞数量、亚群和定量免疫球蛋白水平的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to compare the response rate, time to progression and survival for patients with low-grade lymphoma treated with the Cyclophosphamide/Fludarabine regimen with a control arm of standard CVP. The study will also determine the effect of maintenance with anti-CD20 on time to progression and survival and its effect on lymphocytic number, subsets and quantitative immunoglobin levels over time.